Analyst Ratings For Sorrento Therapeutics Inc (NASDAQ:SRNE)
Today, HC Wainwright set its price target on Sorrento Therapeutics Inc (NASDAQ:SRNE) to $40.00 per share.
There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Sorrento Therapeutics Inc (NASDAQ:SRNE) is Buy with a consensus target price of $21.4167 per share, a potential 675.97% upside.
Some recent analyst ratings include
- 6/28/2018-Sorrento Therapeutics Inc (NASDAQ:SRNE) has coverage initiated with a Buy rating and $14.25 price target
- 8/3/2017-Sorrento Therapeutics Inc (NASDAQ:SRNE) has coverage initiated with a Buy rating and $7.00 price target
- 8/3/2017-Sorrento Therapeutics Inc (NASDAQ:SRNE) has coverage initiated with a Outperform rating and $7.00 price target
- 6/17/2017-Sorrento Therapeutics Inc (NASDAQ:SRNE) had its Buy rating reiterated by FBR & Co
- On 9/13/2018 Abg Management Ltd, Major Shareholder, sold 297,568 with an average share price of $5.02 per share and the total transaction amounting to $1,493,791.36.
- On 2/28/2018 George K Ng, Insider, bought 90,000 with an average share price of $9.95 per share and the total transaction amounting to $895,500.00.
- On 2/7/2018 Abg Management Ltd, Major Shareholder, sold 150,000 with an average share price of $7.19 per share and the total transaction amounting to $1,078,500.00.
- On 2/5/2018 Abg Management Ltd, Major Shareholder, sold 70,721 with an average share price of $8.00 per share and the total transaction amounting to $565,768.00.
- On 1/30/2018 Abg Management Ltd, Major Shareholder, sold 310,000 with an average share price of $7.64 per share and the total transaction amounting to $2,368,400.00.
- On 1/24/2018 Pacific Medtech (Bvi) Ltd Asia, Major Shareholder, sold 684,288 with an average share price of $7.56 per share and the total transaction amounting to $5,173,217.28.
- On 6/15/2017 Henry Ji, Insider, bought 29,001 with an average share price of $1.81 per share and the total transaction amounting to $52,491.81.
About Sorrento Therapeutics Inc (NASDAQ:SRNE)
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Recent Trading Activity for Sorrento Therapeutics Inc (NASDAQ:SRNE)
Shares of Sorrento Therapeutics Inc closed the previous trading session at 2,76 +0,085 3,18 % with 1148252 shares trading hands.